Cassava Sciences Welcomes Dawn C. Bir to Board of Directors

Author: Addison Perry Updated: 10-22-2025 08:22 AM

Cassava Sciences Enhances Leadership with New Board Appointment

Cassava Sciences, Inc. (NASDAQ: SAVA), a biotechnology company devoted to creating innovative treatments for central nervous system (CNS) disorders, announced recently that Ms. Dawn C. Bir has been appointed to its Board of Directors.

Ms. Dawn C. Bir: A Proven Biopharmaceutical Leader

Dawn Bir brings extensive experience to Cassava, having previously helped guide several biopharmaceutical companies through significant growth and transition phases. Her background includes key executive roles at notable organizations like Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics, demonstrating a strong ability to drive both clinical and commercial success.

Creating Shareholder Value

Claude Nicaise, MD, Chairman of the Board at Cassava, expressed enthusiasm about Ms. Bir's addition to the leadership team during a transformative time for the company. He stated, "Her commitment to enhancing shareholder value will be a valuable asset, and we eagerly anticipate the positive impact of her contributions.”

Preparing for Clinical Advancements

As Cassava readies itself for the initiation of its first clinical study of simufilam targeting TSC-related epilepsy, Rick Barry, the company's President and CEO, emphasized the need for strategic capabilities within the Board. He noted Ms. Bir's proven track record in establishing impactful relationships within the industry would be crucial as they advance their programs.

A Call to Action in CNS Research

Ms. Bir echoed this sentiment, highlighting the urgent need for new therapeutic options for TSC-related epilepsy. She expressed her excitement about working closely with Cassava’s committed management team to navigate the company’s business and clinical strategies, aiming to deliver significant advancements in treatment options for patients and their families.

About Cassava Sciences, Inc.

Cassava Sciences (NASDAQ: SAVA) is focused on innovative treatment solutions like simufilam for CNS disorders, including TSC-related epilepsy. Simufilam is a proprietary oral small molecule that aims to modulate the activity of the filamin A protein, which plays a vital role in neuronal development. The company's base of operations is located in Austin, Texas.

Contact Information

For further inquiries, interested parties can reach out to:
Investors:
Sandya von der Weid
Email: svonderweid@lifesciadvisors.com
Company:
Eric Schoen, Chief Financial Officer
(512) 501-2450
Email: ESchoen@CassavaSciences.com
IR@cassavasciences.com

Frequently Asked Questions

What is the main focus of Cassava Sciences?

Cassava Sciences is dedicated to developing novel treatments for central nervous system disorders, including epilepsy associated with Tuberous Sclerosis Complex.

Who is Dawn C. Bir?

Dawn C. Bir is a seasoned biopharmaceutical executive, newly appointed to the Board of Directors at Cassava Sciences.

What role does the Board play in Cassava's strategy?

The Board provides strategic oversight and direction, particularly as the company prepares for clinical advancements in their product pipeline.

What is simufilam?

Simufilam is an investigational treatment currently being developed by Cassava Sciences for TSC-related epilepsy and other CNS disorders.

How can investors contact Cassava Sciences?

Investors can reach out to the CFO via email at ESchoen@CassavaSciences.com for inquiries.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.